Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$171.06M

FY 2025 · Annual

Investing Cash Flow

-$240.29M

FY 2025 · Annual

Financing Cash Flow

$17.77M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(1.84B)(2.11B)(892.87M)(547.03M)(312.76M)
Depreciation & Amortization29.08M42.55M71.55M63.02M58.99M
Deferred Income Tax30.21M(14.61M)(801K)(936K)(1.36M)
Stock-Based Compensation1.61B1.93B229.88M112.34M81.55M
Change in Working Capital(61.54M)(37.01M)29.84M(89.67M)(44.09M)
Accounts Receivables(114.09M)55.02M50.07M(4.73M)(1.47M)
Inventory(626K)164K000
Accounts Payables(2.25M)(10.84M)(1.18M)4.77M(2.99M)
Other Working Capital55.43M(81.35M)(19.05M)(89.72M)(39.62M)
Other Non-Cash Items(20.95M)(67.4M)266.9M142.69M46.62M
Operating Cash Flow(253.82M)(252.2M)(295.5M)(319.59M)(171.06M)
Capital Expenditures(56.52M)(52.27M)(40.8M)(62.54M)(7.67M)
Acquisitions (Net)(12.04M)26.65M(38.55M)(5.4M)0
Purchases of Investments(5M)(3.69M)00(418.63M)
Sales of Investments0004.52M185.38M
Other Investing Activities304K(38.08M)(1.34M)1.19M624K
Investing Cash Flow(73.26M)(67.39M)(80.69M)(62.24M)(240.29M)
Debt Repayment(1.12M)(1.24M)(1.3M)(897K)(354K)
Common Stock Issued099.3M080K19.47M
Common Stock Repurchased(25M)0(23K)00
Dividends Paid00000
Other Financing Activities1.56B(2.73M)(1.43M)(922K)(1.34M)
Financing Cash Flow1.53B95.34M(3.22M)(1.74M)17.78M
Effect of Forex Changes(19K)908K(588K)(281K)395K
Net Change in Cash1.21B(223.35M)(380M)(383.84M)(393.18M)
Free Cash Flow(310.34M)(304.47M)(336.3M)(382.13M)(178.72M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$312.8M
+ D&A$59.0M
+ Stock-Based Comp$81.5M
- Deferred Tax-$1.4M
- Working Capital-$44.1M
+ Other Non-Cash$46.6M
= Operating Cash Flow-$171.1M
- Capex-$7.7M
= Free Cash Flow-$178.7M

Analysis

FY2025 free cash flow is -$178.7M. FCF conversion is 57.1% of net income. Operating cash flow was -$171.1M, with capex of -$7.7M. The largest bridge item is Stock-Based Comp at $81.5M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 5, 2026
8-KCurrent reportOct 29, 2026
4Statement of changes in beneficial ownershipOct 21, 2026
4Statement of changes in beneficial ownershipOct 21, 2026

Does DNA generate free cash flow?

Ginkgo Bioworks Holdings, Inc. (DNA) generated -$178.72M of free cash flow in fiscal 2025.

How much operating cash flow does DNA produce?

Operating cash flow was -$171.06M, before capital expenditures of $7.67M.